Print

Mirada Medical Announces Release of XD3.4 at the Society of Nuclear Medicine Annual Meeting, San Antonio, Texas  
6/6/2011 9:30:21 AM

OXFORD, UNITED KINGDOM and PHILADELPHIA, PA--(Marketwire - June 06, 2011) - Mirada Medical, a leading provider of oncology imaging software for multidisciplinary cancer teams, announced today the release of XD3.4, the latest version of the company's advanced diagnostics software. Mirada is currently showcasing its oncology portfolio at the Society of Nuclear Medicine (SNM) Annual Meeting in San Antonio, Texas.

With this latest release, users will be able to display, quantify and track lesions on gated data, multi-phase CT and multi-sequence MR. All of the clinical tools available for PET, CT, MR, SPECT are now also available for these advanced studies including powerful fusion, and propagation of measurements and findings across gates, sequences, and unlimited timepoints. The addition of elegant workflows for these complex studies makes XD3.4 the most comprehensive diagnostic oncology imaging software on the market.

"Scanners today can produce sophisticated data showing motion of organs and lesions, but often there is no software provided which can really leverage the diagnostic power of the images produced," says Dr. Timor Kadir, Chief Scientist at Mirada. "We have built the tools and technology for clinical experts to properly load, display and work with large volumes of gated, multi-phase and multi-sequence data without having to compromise on speed or quality. No other diagnostic software available today can provide this level of support for clinical decision-making in oncology imaging."

Focusing on clinical questions as the foundation for development, Mirada built innovative 4D multi-modality data workflows unique to XD3.4 to support disease-specific diagnosis, staging, therapy planning and treatment response evaluation. Simultaneous and customizable display of a PET alongside a multiphase CT scan allows a comprehensive overview of both biological tumor activity and different phases of contrast enhancement patterns. This enables, for example, better combined assessment of the vascularization and metabolism of a suspicious liver or pancreatic lesion. Multiple timepoint display of gated PET, PET/CT, CT, Planar NM and SPECT data enables superior qualitative and quantitative assessment of tracer accumulation as well as tracking the extent and effects of intrinsic motion on a suspicious lesion, for example, in the thorax.

The XD3.4 release also comprises a number of significant performance features; additional user preference settings, smart VOI editing tools and fast data swapping within workflows are all targeted at increasing efficiency in those tasks which are most time consuming and repetitive.

Together with optimized workflows for PET/CT reading, triple modality fusion and software fusion based MR-PET, the new XD3.4 release from Mirada is the essence of the company's innovative approach to diagnostic imaging in oncology. Mirada's full portfolio of software including XD3.4 is on show at SNM, booth 4027, until June 7th.

About Mirada Medical
Mirada Medical is an internationally recognized brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.

Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis.

Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at tumor board.

Mirada announces release of XD3.4: http://hugin.info/143183/R/1521166/457365.pdf


For more information, please contact:
Mirada Medical
Europe:
Hugh Bettesworth
CEO
tel: +44 (0) 1865 261410

US:
Mary Beth Archibald
EVP US Service and Operations
tel: +1 816 536 8385
enquiries@mirada-medical.com
www.mirada-medical.com


//-->